Johnson & Johnson (NYSE:JNJ) Stock Holdings Lowered by Knuff & Co LLC

Key Points

• Knuff & Co LLC reduced its holdings in Johnson & Johnson by 15.3%, owning 7,957 shares worth approximately $1.32 million after selling 1,437 shares in the first quarter.
• Johnson & Johnson's recent quarterly earnings showed an EPS of $2.77, surpassing consensus estimates and achieving a net revenue of $23.74 billion, up 5.8% year-over-year.
• The company has announced a quarterly dividend of $1.30 per share, reflecting a dividend yield of 2.9% and a payout ratio of 55.61%.

Knuff & Co LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 15.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,957 shares of the company's stock after selling 1,437 shares during the quarter. Knuff & Co LLC's holdings in Johnson & Johnson were worth $1,320,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. Raymond James Financial Inc. increased its position in shares of Johnson & Johnson by 2.2% in the first quarter. Raymond James Financial Inc. now owns 9,468,114 shares of the company's stock worth $1,570,192,000 after acquiring an additional 203,291 shares in the last quarter. Alliance Wealth Advisors LLC UT increased its position in Johnson & Johnson by 32.1% in the 1st quarter. Alliance Wealth Advisors LLC UT now owns 10,151 shares of the company's stock worth $1,683,000 after purchasing an additional 2,465 shares during the last quarter. Forvis Mazars Wealth Advisors LLC raised its stake in shares of Johnson & Johnson by 37.6% during the 1st quarter. Forvis Mazars Wealth Advisors LLC now owns 58,656 shares of the company's stock worth $9,728,000 after purchasing an additional 16,019 shares in the last quarter. American Investment Services Inc. lifted its holdings in shares of Johnson & Johnson by 56.7% during the 1st quarter. American Investment Services Inc. now owns 15,839 shares of the company's stock valued at $2,627,000 after buying an additional 5,733 shares during the last quarter. Finally, Gen Wealth Partners Inc grew its stake in shares of Johnson & Johnson by 7.0% in the 1st quarter. Gen Wealth Partners Inc now owns 14,563 shares of the company's stock valued at $2,415,000 after buying an additional 956 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ opened at $176.76 on Friday. The stock has a market capitalization of $425.70 billion, a P/E ratio of 18.90, a P/E/G ratio of 2.23 and a beta of 0.41. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $177.27. The company has a 50 day moving average of $161.28 and a 200-day moving average of $158.34. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business's quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the business earned $2.82 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Analyst Ratings Changes

JNJ has been the subject of several recent research reports. Royal Bank Of Canada boosted their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. Barclays boosted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Guggenheim restated a "neutral" rating and issued a $167.00 price objective (up from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Nine analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.